ZERO Prostate Cancer Welcomes Two New Medical Advisory Board Members Dr. Jonathan Leeman and Dr. Leanne Woods-Burnham April 11, 2024 FOR IMMEDIATE RELEASEMedia Contact:Stephanie S. JohnsonZERO Prostate Cancerstephjohnson@zerocancer.org | media@zerocancer.org(202) 998-2507 Leading Experts Enhance Support and Address Health Disparities in Prostate CancerWashington, D.C., April 11, 2024 - ZERO Prostate Cancer proudly announces the appointment of Dr. Jonathan Leeman and Dr. Leanne Woods-Burnham to its national Medical Advisory Board. Dr. Leeman and Dr. Woods-Burnham bring a unique perspective and expertise to the multidisciplinary team of medical professionals serving on ZERO’s Medical Advisory Board. Dr. Jonathan Leeman, Director of MRI guided radiotherapy at Brigham and Women’s Hospital in Boston, MA and Assistant Professor of Radiation Oncology at Harvard Medical School, brings extensive prostate cancer treatment knowledge to ZERO's Medical Advisory Board. Dr. Leeman received his AB from Harvard College and is a graduate of the Physician Scientist Training Program at the University of Pittsburgh School of Medicine. He completed his internship and residency in radiation oncology at Memorial Sloan Kettering Cancer Center in New York, NY, where he served as Chief Resident. His clinical knowledge in MRI-guided and adaptive radiotherapy and his dedication to improving treatment outcomes and reducing side effects will help inform and advance ZERO’s education and support programs. Dr. Leanne Woods-Burnham, Assistant Professor at Morehouse School of Medicine, Atlanta, GA, specializes in prostate cancer health disparities. With a B.S. in biology from The University of Akron and a Ph.D. in physiology from Loma Linda University, Dr. Burnham's research focuses on ancestry-associated HER2 expression in Black men with prostate cancer, aiming to improve clinical outcomes. Currently funded by various organizations, including the Department of DefenseProstate Cancer Research Program and NIH/NIMHD Research Centers for Minority Institutions U54 award, she leads translational race-stratified studies and co-directs the Prostate Cancer Precision Prevention Program (PCP3), providing health education and PSA tests to at-risk men in Atlanta and rural Georgia. Recognized for her work by Cell’s #FacesofCell and The Cancer Health 25: Black Lives Matter campaigns, Dr. Burnham is dedicated to breaking down racial barriers in cancer care."I am delighted to welcome Dr. Jonathan Leeman and Dr. Leanne Woods-Burnham to our Medical Advisory Board," said Courtney Bugler, President & CEO of ZERO Prostate Cancer. "Their wealth of knowledge and expertise in prostate cancer treatment, health disparities, and community outreach will further enhance our ability to provide comprehensive support and education to patients and families when they need it the most."ZERO's Medical Advisory Board plays a vital role in providing strategic guidance and direction for mission delivery, policy, programs, and resources to empower all who are impacted by the disease. In addition to bringing a wide variety of expertise, including clinical and laboratory research, to surgery, survivorship, social work, and other disciplines and specialties, Medical Advisory Board Members serve as community ambassadors for the organization nationwide.For more information about ZERO Prostate Cancer’s Medical Advisory Board, please click here. About ZERO Prostate CancerZERO Prostate Cancer (ZERO) is on a mission to improve and save lives from prostate cancer through advocacy, education, awareness, and support. Formerly known as the National Prostate Cancer Coalition, ZERO was founded in 1996 to stand up for people impacted by prostate cancer. Today, ZERO serves as the nation's leading prostate cancer organization, advancing a future where prostate cancer detection is early, support is unwavering, and care is accessible to all. For almost 30 years, ZERO has led the way in prostate cancer advocacy and support, successfully unlocking funding toward breakthrough discoveries, treatments, and lifesaving access to care.As the nation's #1 provider of prostate cancer resources, programs, and services, ZERO has supported millions of people at-risk or diagnosed, and their families. As the voice of the prostate cancer community, ZERO's urgent focus on breaking barriers to survival—by closing gaps in diagnosis, treatment, and care—brings critical attention to those most likely to be impacted by this disease. Learn more at ZEROCancer.org. About ZERO Health Equity Press Release Racial & Social Disparities More for you
ZERO Prostate Cancer Welcomes Two New Medical Advisory Board Members Dr. Jonathan Leeman and Dr. Leanne Woods-Burnham April 11, 2024
FOR IMMEDIATE RELEASEMedia Contact:Stephanie S. JohnsonZERO Prostate Cancerstephjohnson@zerocancer.org | media@zerocancer.org(202) 998-2507
Leading Experts Enhance Support and Address Health Disparities in Prostate CancerWashington, D.C., April 11, 2024 - ZERO Prostate Cancer proudly announces the appointment of Dr. Jonathan Leeman and Dr. Leanne Woods-Burnham to its national Medical Advisory Board. Dr. Leeman and Dr. Woods-Burnham bring a unique perspective and expertise to the multidisciplinary team of medical professionals serving on ZERO’s Medical Advisory Board. Dr. Jonathan Leeman, Director of MRI guided radiotherapy at Brigham and Women’s Hospital in Boston, MA and Assistant Professor of Radiation Oncology at Harvard Medical School, brings extensive prostate cancer treatment knowledge to ZERO's Medical Advisory Board. Dr. Leeman received his AB from Harvard College and is a graduate of the Physician Scientist Training Program at the University of Pittsburgh School of Medicine. He completed his internship and residency in radiation oncology at Memorial Sloan Kettering Cancer Center in New York, NY, where he served as Chief Resident. His clinical knowledge in MRI-guided and adaptive radiotherapy and his dedication to improving treatment outcomes and reducing side effects will help inform and advance ZERO’s education and support programs. Dr. Leanne Woods-Burnham, Assistant Professor at Morehouse School of Medicine, Atlanta, GA, specializes in prostate cancer health disparities. With a B.S. in biology from The University of Akron and a Ph.D. in physiology from Loma Linda University, Dr. Burnham's research focuses on ancestry-associated HER2 expression in Black men with prostate cancer, aiming to improve clinical outcomes. Currently funded by various organizations, including the Department of DefenseProstate Cancer Research Program and NIH/NIMHD Research Centers for Minority Institutions U54 award, she leads translational race-stratified studies and co-directs the Prostate Cancer Precision Prevention Program (PCP3), providing health education and PSA tests to at-risk men in Atlanta and rural Georgia. Recognized for her work by Cell’s #FacesofCell and The Cancer Health 25: Black Lives Matter campaigns, Dr. Burnham is dedicated to breaking down racial barriers in cancer care."I am delighted to welcome Dr. Jonathan Leeman and Dr. Leanne Woods-Burnham to our Medical Advisory Board," said Courtney Bugler, President & CEO of ZERO Prostate Cancer. "Their wealth of knowledge and expertise in prostate cancer treatment, health disparities, and community outreach will further enhance our ability to provide comprehensive support and education to patients and families when they need it the most."ZERO's Medical Advisory Board plays a vital role in providing strategic guidance and direction for mission delivery, policy, programs, and resources to empower all who are impacted by the disease. In addition to bringing a wide variety of expertise, including clinical and laboratory research, to surgery, survivorship, social work, and other disciplines and specialties, Medical Advisory Board Members serve as community ambassadors for the organization nationwide.For more information about ZERO Prostate Cancer’s Medical Advisory Board, please click here.
About ZERO Prostate CancerZERO Prostate Cancer (ZERO) is on a mission to improve and save lives from prostate cancer through advocacy, education, awareness, and support. Formerly known as the National Prostate Cancer Coalition, ZERO was founded in 1996 to stand up for people impacted by prostate cancer. Today, ZERO serves as the nation's leading prostate cancer organization, advancing a future where prostate cancer detection is early, support is unwavering, and care is accessible to all. For almost 30 years, ZERO has led the way in prostate cancer advocacy and support, successfully unlocking funding toward breakthrough discoveries, treatments, and lifesaving access to care.As the nation's #1 provider of prostate cancer resources, programs, and services, ZERO has supported millions of people at-risk or diagnosed, and their families. As the voice of the prostate cancer community, ZERO's urgent focus on breaking barriers to survival—by closing gaps in diagnosis, treatment, and care—brings critical attention to those most likely to be impacted by this disease. Learn more at ZEROCancer.org.
